Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation

Open-label, Randomized, Single-dose, 2-way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Sublingual Tablet

This study tests the assumption that the bioavailability of alprazolam from a new sublingual formulation is the same as that from sublingual formulation expected to be used commercially in Brazil.

Inclusion Criteria:

• Healthy male or female subjects
• BMI 17.5 - 30.5
• Must provide informed consent

Exclusion Criteria:

• Clinically significant disease
• Narrow angle glaucoma
• Positive drug screen